United Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs Group

United Therapeutics (NASDAQ:UTHR) had its price target raised by The Goldman Sachs Group from $243.00 to $302.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price points to a potential downside of 19.66% from the stock’s previous close.

UTHR has been the subject of a number of other reports. Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $310.00 to $321.00 in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Price Performance

Shares of UTHR stock traded up $1.95 during mid-day trading on Friday, hitting $375.92. 210,651 shares of the stock traded hands, compared to its average volume of 465,637. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.92. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The company’s 50-day simple moving average is $354.88 and its 200-day simple moving average is $315.69. The firm has a market cap of $16.72 billion, a price-to-earnings ratio of 16.51, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period in the previous year, the business earned $5.38 earnings per share. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, equities research analysts expect that United Therapeutics will post 24.75 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $833,350.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares in the company, valued at approximately $947,597.55. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,412 shares of company stock valued at $33,971,508. Insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of UTHR. SG Americas Securities LLC raised its holdings in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after buying an additional 4,100 shares during the period. Comerica Bank lifted its position in United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares during the last quarter. Tri Locum Partners LP bought a new stake in shares of United Therapeutics during the second quarter worth approximately $15,959,000. Finally, QRG Capital Management Inc. grew its position in shares of United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.